Daniel P Hart

List of Publications by Year
in descending order

33 papers	1,442 citations	516710 16 h-index	454955 30 g-index
35 all docs	35 docs citations	35 times ranked	1937 citing authors

#	Article	IF	Citations
1	Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. New England Journal of Medicine, 2020, 383, 288-290.	27.0	418
2	Diagnosis and treatment of factor <scp>VIII</scp> and <scp>IX</scp> inhibitors in congenital haemophilia: (4th edition). British Journal of Haematology, 2013, 160, 153-170.	2.5	192
3	Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood, 2013, 122, 1954-1962.	1.4	188
4	Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood, 2014, 124, 3389-3397.	1.4	110
5	Haemophilia. Nature Reviews Disease Primers, 2021, 7, 45.	30.5	103
6	Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia, 2019, 25, 205-212.	2.1	51
7	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	2.3	50
8	Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients. PLoS ONE, 2017, 12, e0169880.	2.5	39
9	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	1.4	34
10	Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thrombosis and Haemostasis, 2015, 114, 46-55.	3.4	33
11	Delivery of AAVâ€based gene therapy through haemophilia centresâ€”A need for reâ€evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC. Haemophilia, 2021, 27, 967-973.	2.1	29
12	Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies. Haemophilia, 2019, 25, 398-407.	2.1	27
13	Preâ€analytical heat treatment and a <scp>FVIII ELISA</scp> improve Factor <scp>VIII</scp> antibody detection in acquired haemophilia A. British Journal of Haematology, 2014, 166, 953-956.	2.5	24
14	Treatment burden, haemostatic strategies and real world inhibitor screening practice in nonâ€severe haemophilia A. British Journal of Haematology, 2017, 176, 796-804.	2.5	21
15	Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Thrombosis and Haemostasis, 2015, 114, 804-811.	3.4	19
16	A largeâ€scale computational study of inhibitor risk in nonâ€severe haemophilia A. British Journal of Haematology, 2015, 168, 413-420.	2.5	19
17	Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia, 2021, 27, 932-937.	2.1	16
18	Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study. Orphanet Journal of Rare Diseases, 2021, 16, 189.	2.7	15

#	Article	IF	Citations
19	International consensus recommendations on the management of people with haemophilia B. Therapeutic Advances in Hematology, 2022, 13, 204062072210852.	2.5	13
20	Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC. Haemophilia, 2022, 28, .	2.1	10
21	Re-personalization and stratification of hemophilia care in an evolving treatment landscape. Hematology, 2019, 24, 737-741.	1.5	6
22	Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A. Haematologica, 2019, 104, 599-608.	3.5	6
23	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq1 1 0.784314 rgBT /Overl 2021, 27, 911-920.	2.1	5
24	Letter in response to: Coagulation markers are independent predictors of increased oxygen requirements and thrombosis in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 3382-3384.	3.8	4
25	Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey. Haemophilia, 2021, 27, 490-499.	2.1	2
26	Von Willebrand factor. Clinical Medicine, 2020, 20, e279-e279.	1.9	2
27	Perioperative laboratory monitoring in congenital haemophilia patients with inhibitors. Blood Coagulation and Fibrinolysis, 2019, 30, 309-323.	1.0	1
28	The factor VIII treatment history of nonâ€severe hemophilia Aâ€”Response from original authors Abdi et al. Journal of Thrombosis and Haemostasis, 2021, 19, 2642-2644.	3.8	1
29	A Two Centre Experience Of Use Of a Dual Virally Inactivated FVIII/VWF Product (WilateÂ®) In Patients With Von Willebrand Disease. Blood, 2013, 122, 1112-1112.	1.4	1
30	FVIII Immunogenicityâ€”Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A. Frontiers in Immunology, 2020, 11, 1498.	4.8	0
31	Commentary on â€œDevelopment of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approachâ€•â€•Will we ever be able to avoid inhibitor formation in hemophilia A?. Journal of Thrombosis and Haemostasis, 2021, 19, 2125-2126.	3.8	0
32	Managing Acquired Haemophilia (A): Pan London Experience-Relating to the European Acquired Haemophilia (EACH2) Registry Data. Blood, 2014, 124, 1512-1512.	1.4	0
33	New challenges for an expanding generation of older persons with haemophilia. The Journal of Haemophilia Practice, 2022, 9, 1-13.	0.4	0